Home
APTO
APTO News

Latest Aptose Biosciences Inc. (APTO) News on February 23, 2025

MT Newswires

3 days ago

Aptose Surges 48% in U.S. Pre-market After Safety Review Committee Approves Doubling Tuspetinib Dose

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

GlobeNewswire

3 days ago

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Reverse Share Split

GlobeNewswire

5 days ago

Aptose Announces Reverse Share Split

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

GlobeNewswire

10 days ago

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

MT Newswires

11 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

11 days ago

Top Midday Gainers

MT Newswires

11 days ago

Aptose Up 20% In US Premarket After Update On Its Frontline Triple Drug Therapy With Tuspetinib

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

GlobeNewswire

11 days ago

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

MT Newswires

a month ago

Aptose Biosciences Initiates Dosing in Early Study of Acute Myeloid Leukemia Treatment

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

GlobeNewswire

a month ago

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

MT Newswires

2 months ago

Top Midday Gainers

MT Newswires

2 months ago

Top Premarket Gainers

Aptose Announces Positive Decision by Nasdaq Hearings Panel

GlobeNewswire

2 months ago

Aptose Announces Positive Decision by Nasdaq Hearings Panel

MT Newswires

2 months ago

Aptose Says Tusepetinib Preclinical Data Published in AACR Journal

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

GlobeNewswire

2 months ago

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

GlobeNewswire

2 months ago

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

MT Newswires

3 months ago

Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

GlobeNewswire

3 months ago

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

MT Newswires

3 months ago

Aptose Biosciences Closes US$8 Million Public Offering

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

GlobeNewswire

3 months ago

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

Benzinga

3 months ago

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

MT Newswires

3 months ago

Aptose Biosciences Prices $8 Million Securities Sale

MT Newswires

3 months ago

Aptose Biosciences Plunges 35% in Premarket Trade as Prices US$8 Million Public Offering

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

GlobeNewswire

3 months ago

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

MT Newswires

3 months ago

Aptose Biosciences Initiates Phase 1/2 Study for Newly Diagnosed Acute Myeloid Leukemia Patients

MT Newswires

3 months ago

Aptose Biosciences Down 5% in U.S. Premarket, Initiates Study for Newly Diagnosed AML Patients

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

GlobeNewswire

3 months ago

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Reports Results for the Third Quarter 2024

GlobeNewswire

3 months ago

Aptose Reports Results for the Third Quarter 2024

Aptose Announces Results from Special Meeting of Shareholders

GlobeNewswire

6 months ago

Aptose Announces Results from Special Meeting of Shareholders

MT Newswires

6 months ago

Top Premarket Gainers

Aptose Biosciences secures funds for AML treatment development

Pharmaceutical Technology

6 months ago

Aptose Biosciences secures funds for AML treatment development

MT Newswires

6 months ago

Aptose Biosciences Up 65% In US After Hours As Gets US$10 Million Loan From Hanmi Pharmaceutical

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

GlobeNewswire

6 months ago

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Adjournment of its Special Meeting of Shareholders

GlobeNewswire

6 months ago

Aptose Announces Adjournment of its Special Meeting of Shareholders

Associated Press Finance

6 months ago

Aptose Biosciences: Q2 Earnings Snapshot

Aptose Reports Results for the Second Quarter 2024

GlobeNewswire

6 months ago

Aptose Reports Results for the Second Quarter 2024

Aptose Announces Receipt of Deficiency Notice from Nasdaq

GlobeNewswire

7 months ago

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Announces Results from Annual and Special Meeting of Shareholders

GlobeNewswire

8 months ago

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

GlobeNewswire

8 months ago

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

8 months ago

Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

8 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

8 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

8 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

8 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

8 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

8 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

8 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

8 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

MT Newswires

9 months ago

Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

9 months ago

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

9 months ago

Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

9 months ago

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

9 months ago

Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses

Associated Press Finance

9 months ago

Aptose Biosciences: Q1 Earnings Snapshot

Aptose Reports Results for the First Quarter 2024

GlobeNewswire

9 months ago

Aptose Reports Results for the First Quarter 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

GlobeNewswire

10 months ago

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

What Makes Aptose Biosciences (APTO) a New Buy Stock

Zacks

a year ago

What Makes Aptose Biosciences (APTO) a New Buy Stock

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript

Aptose Reports Results for the Fourth Quarter and Full Year 2023

GlobeNewswire

a year ago

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

GlobeNewswire

a year ago

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Zacks

a year ago

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

GlobeNewswire

a year ago

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Intellicheck Achieves ISO/IEC 27001:2013 and ISO/IEC 27001:2019 Recertification

Business Wire

a year ago

Intellicheck Achieves ISO/IEC 27001:2013 and ISO/IEC 27001:2019 Recertification

This Aptose Biosciences Insider Increased Their Holding In The Last Year

Simply Wall St.

a year ago

This Aptose Biosciences Insider Increased Their Holding In The Last Year

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

ACCESSWIRE

a year ago

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

GlobeNewswire

a year ago

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Mullen Super-Crossover Five RS Spotlighted in AutoCar Article

NewMediaWire

a year ago

Mullen Super-Crossover Five RS Spotlighted in AutoCar Article

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

GlobeNewswire

a year ago

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

Business Wire

a year ago

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Vista Gold Corp. Announces Strategic Update and 2024 Outlook

Business Wire

a year ago

Vista Gold Corp. Announces Strategic Update and 2024 Outlook

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

Simply Wall St.

a year ago

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Q3 2024 Earnings Call Transcript

Insider Monkey

a year ago

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Q3 2024 Earnings Call Transcript

Snail Games' ARKade Ambassador Program Reshapes Gaming Connections

GlobeNewswire

a year ago

Snail Games' ARKade Ambassador Program Reshapes Gaming Connections

Business Wire

a year ago

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

Apollomics to Present at the 2024 Biotech Showcase

GlobeNewswire

a year ago

Apollomics to Present at the 2024 Biotech Showcase

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire

a year ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

GlobeNewswire

a year ago

PhenixFIN Corporation Announces Fiscal Year and Fourth Quarter 2023 Financial Results

Business Wire

a year ago

GAN Announces Changes to its Board of Directors

Amtech (NASDAQ:ASYS) Reports Weak Q4

StockStory

a year ago

Amtech (NASDAQ:ASYS) Reports Weak Q4

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire

a year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

ATI PHYSICAL THERAPY INAUGURATES 40TH LOCATION IN MASSACHUSETTS

PR Newswire

a year ago

ATI PHYSICAL THERAPY INAUGURATES 40TH LOCATION IN MASSACHUSETTS

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

GlobeNewswire

a year ago

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication

Exec Edge

a year ago

Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Newsfile

a year ago

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

GlobeNewswire

a year ago

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Senstar Technologies Reports Third Quarter 2023 Financial Results

PR Newswire

a year ago

Senstar Technologies Reports Third Quarter 2023 Financial Results

PR Newswire

a year ago

CLPS Incorporation Declares Second Special Cash Dividend of $0.10 Per Share

Finance of America Chooses Spera Security to Bolster its Identity Security

GlobeNewswire

a year ago

Finance of America Chooses Spera Security to Bolster its Identity Security

Cheetah Net Supply Chain Services Inc. Executes Letter of Intent to Acquire Edward Transit Express Group Inc.

GlobeNewswire

a year ago

Cheetah Net Supply Chain Services Inc. Executes Letter of Intent to Acquire Edward Transit Express Group Inc.

Business Wire

a year ago

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

Calculating The Intrinsic Value Of Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG)

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG)

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript

Associated Press Finance

a year ago

Aptose Biosciences: Q3 Earnings Snapshot

Aptose Reports Results for the Third Quarter 2023

GlobeNewswire

a year ago

Aptose Reports Results for the Third Quarter 2023

Thomson Reuters StreetEvents

a year ago

Q3 2023 Matinas BioPharma Holdings Inc Earnings Call

BK Technologies Corp (BKTI) Reports Significant Revenue Growth and Profitability in Q3 2023

GuruFocus.com

a year ago

BK Technologies Corp (BKTI) Reports Significant Revenue Growth and Profitability in Q3 2023

GuruFocus.com

a year ago

MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges

MiNK Therapeutics Reports Third Quarter 2023 Results

GlobeNewswire

a year ago

MiNK Therapeutics Reports Third Quarter 2023 Results

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

Business Wire

a year ago

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

Share on Social Networks: